Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Aktiespararna's Aktiedagen 2021
24 slides from Expres2ion Biotech Holding Ab's conference presentation, Mar 16, 2021
Slide 1: Proteins for Life
Aktiespararna’s Proteins Aktiedagen for Life Stockholm, Sweden 16 March, 2021 Bent U. Frandsen, CEO Proteins for Life
Slide 2: Forward-looking statements and disclaimer
Forward-looking statements and disclaimer This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this pre
Slide 3: Equity Story
Equity Story • A Scandinavian clinical-stage biotechnology company • Founded in 2010 as ExpreS2ion Biotechnologies ApS in Denmark • Listed in 2016 on Nasdaq First North Growth Market Stockholm as ExpreS2ion Biotech Holding AB (Market Value growth €5M → >€100M) • Creation in 2017 of AdaptVac ApS, a j
Slide 4: Broad Clinical Stage Pipeline
Broad Clinical Stage Pipeline Addressing high medical needs with development partner potential Pre-clinical DISEASE Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Partners / Funding PREVENT-nCOV Corona virus ABNCoV2/SARS-CoV-2 cVLP I / II Breast cancer ES2B-C001/Her2 cVLP
Slide 5: ABNCoV2: cVLP COVID-19 Program (I)
ABNCoV2: cVLP COVID-19 Program (I) Promising preclinical data support the clinical Phase I/II study now initated Neutralising antibodies vaccination (small animals) • Capsid virus like particle (cVLP) based SARS-CoV-2 subunit vaccine • Funded by EU until clinical Ph I/II, within the PREVENT-nCoV con
Slide 6: ABNCoV2: cVLP COVID-19 Program (II)
ABNCoV2: cVLP COVID-19 Program (II) Phase I/II open label, dose-escalation trial initiated • Initiation of a first-in-human study, supported by the Purpose Horizon 2020 EU grant, announced March 8, 2021 The aim of is to test the safety and possible side effects of • First volunteer enrolled and firs
Slide 7: ABNCoV2: cVLP COVID-19 Program (III)
ABNCoV2: cVLP COVID-19 Program (III) Bavarian Nordic’s NHP study data, and recent cash raising, reinforce license commitment Neutralizing antibodies Viral load after challenge A single administration of low and Following a challenge with • Bavarian Nordic-sponsored non-human high dose with adjuvant,
Slide 8: ABNCoV2: cVLP COVID-19 Program (IV)
ABNCoV2: cVLP COVID-19 Program (IV) Potential economics of the license agreements – illustrative example of cash flow from royalties License (VLP) License (S2) Agreement Agreement • EUR 4m upfront (paid in July 1) Pipeline milestone payments 2020) Mechanism • Up to EUR 136m in • Up to EUR 2m in comm
Slide 9: Development of HER2-cVLP ES2B-C001 as a promising treatment opportunity of HER2+ breast cancer (I)
Development of HER2-cVLP ES2B-C001 as a promising treatment opportunity of HER2+ breast cancer (I) • Comprehensive preclinical proof of concept data on a similar vaccine candidate Delta 16 F1 • Prevent tumor formation and improve survival in mice mice mice • Superior to trastuzumab in BT-474 human t
Slide 10: Development of HER2-cVLP ES2B-C001 as a promising treatment opportunity of HER2+ breast cancer (II)
Development of HER2-cVLP ES2B-C001 as a promising treatment opportunity of HER2+ breast cancer (II) • Early dialogue with regulatory authorities (FDA/EMA) to mitigate the potential risk of IND/CTA failure Clinical: Competitive Environment • Optimize clinical development program with HER2+ Breast Can
Slide 11: Development of HER2-cVLP ES2B-C001: Deal comparables
Development of HER2-cVLP ES2B-C001 Deal comparables: Select billion-SEK commercial opportunities in licensing partnerships Deal Summary Case I Case II Case III Case IV Deal date September 2020 July 2020 April 2019 November 2018 Licensor/seller Seattle Genetics Radius Health Puma Biotechnology ZymeWo
Slide 12: Influenza and Malaria
Influenza and Malaria Projects progression affected by COVID-19 in 2020, but catching up again now INFLUENZA • EU funding of EUR 10 mio. in EUR 16 mio. project INDIGO • EU-India partner consortium - Next-generation flu vaccines • Subunit flu vaccine with novel CMS adjuvant • Vaccine design completed
Slide 13: Broad Clinical Stage Pipeline
Broad Clinical Stage Pipeline Addressing high medical needs and growing multi billion EUR markets Pre-clinical DISEASE Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Market potential Corona virus ABNCoV2/SARS-CoV-2 cVLP I / II > 30 billion EUR Breast cancer ES2B-C001/Her2
Slide 14: Proteins for Life
Proteins for Life
Slide 15: Advantages of the ExpreS2 Platform
Advantages of the ExpreS2™ Platform S2 vector system patent granted until 2032 (US); glyco-engineered S2 cells pending until 2040 Key benefits Drosophila melanogaster (fruit fly), S2 cells *) Speed & quality Transfection ✓ Fast & high Reducing time to market level protein expression Enabling difficu
Slide 16: Advantages of a cVLP Display Platform
Advantages of a cVLP Display Platform AdaptVac has licensed the technology from Copenhagen University; granted until 2036 (US) Key benefits Increased immunogenicity Simple E. coli based Simple E.coli based VLP production ✓ Directional VLP production presentation ✓ Covalent Faster immune response mix
Slide 17: Proteins for Life
Proteins for Life
Slide 18: Financials (I)
Financials (I) Revenues and Net Result and Cash Position growing at all levels since the 2016-IPO 15.3 107 13.8 9.8 8.9 4.6 Revenues Cash Position at year end Amounts in SEK million 2016* 2017 2018 2019 2020 Net Result -8.5 -9.8 -16.8 -16.7 6 6 5 2 -32.0 2016 2017 2018 2019 2020 *The operations in E
Slide 19: Financials (II)
Financials (II) Exercise of warrant programme TO4 injects new cash in April 2021 • 5.5 million TO4 warrants, part of the recent successfully oversubscribed rights issue • Exercise window April 12-26, 2021 • Strike price equal to 70% of VWAP during 10 trading days prior • Strike price must be within
Slide 20: Management Team
Management Team New amendments add additional skills to pursue our pipeline development strategy • Bent U. Frandsen, CEO • MSc. In Finance/Strategic Management, Copenhagen Business School, Denmark • Born 1967, Danish citizen • >25 years industry finance, business development and management experienc
Slide 21: News Flow
News Flow ✔ ABNCoV2 Initiation of ABNCoV2 Initial safety results ABNCoV2 The vaccine is expected to ABNCoV2 Headline results from ABNCoV2 The vaccine is expected ABNCoV2 Ready for market launch first clinical from COUGH-1 enter Bavarian Nordic- COUGH-1 announced to enter phase II/III in 2022 (subjec
Slide 22: Looking Forward
Looking Forward • Clear roadplan for developing assets towards major value infliction points • Focus on partnering activities for financing & risk sharing of assets • Strengthen revenues with new and larger customers & projects • Continued commitment to obtain non- dilutive financing • Identify new
Slide 23: Proteins for Life
Aktiespararnas Proteins Aktiedagen for Life Stockholm, Sweden 16 March, 2021 Bent U. Frandsen, CEO Proteins for Life
Slide 24: Group Structure
Group Structure NASDAQ First North Growth Market Biotech company ExpreS2ion Biotech Swedish AB 2016 • AB listed in Stockholm in 2016 On NASDAQ First North [EXPRS2] • >6,000 shareholders, Market cap >EUR 100m *) ExpreS2ion Biotechnologies Danish ApS 2010 • ExpreS2 platform developed since 2000 100% o
ExpreS2ion Biotech Holding — Aktiespararna's Aktiedagen 2021 on 6ix